Tirzepatide
Also known as: Mounjaro, Zepbound
Classification
Pharmaceutical
Regulatory Status
FDA-approved prescription product
Sources
3
Review
n/a
Overview
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, improving glycemic control and reducing appetite/energy intake in labeled populations.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-approved dual GIP/GLP-1 receptor agonist products are labeled for type 2 diabetes and for chronic weight management in specified populations; educational reference only.
Interactions & cautions
Flagged in source data
Drug interactions
insulin or insulin secretagogues (e.g., sulfonylureas) — Increased hypoglycemia risk (high)
oral medications with narrow therapeutic index dependent on threshold concentration — May alter absorption of some oral drugs (review)
These are observational flags for review, not individualized instructions.
Sources
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide (opens in a new tab)
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zepbound (opens in a new tab)
- https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss (opens in a new tab)
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw